FDA Grants Fast Track Designation to PT886 for the Treatment of Pancreatic Cancer
PT886 (Phanes Therapeutics) received fast track designation 2 years after receiving orphan drug designation by the FDA.
Stay updated with breaking news from Ming Wang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PT886 (Phanes Therapeutics) received fast track designation 2 years after receiving orphan drug designation by the FDA.
Ambarella, Inc. (NASDAQ:AMBA – Get Free Report) CEO Feng-Ming Wang sold 2,173 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $49.27, for a total value of $107,063.71. Following the sale, the chief executive officer now owns 806,632 shares in the company, valued at […]
As climate change hits the seafood industry, producers are being forced to adapt and seek out new technology...
As climate change hits the seafood industry, producers are being forced to adapt and seek out new technology...